Top Five Takeaways From World's Largest Dermatology Conference

As the American Academy of Dermatology meeting ends in Boston, Scrip looks at some of the key data presented at the congress covering the latest advances in the hot area of atopic dermatitis, alopecia and butterfly skin.

Boston
Boston home to AAD in 2022 • Source: Alamy

Sanofi raised its "sales peak ambition" for Dupixent (dupilumab) to more than €13bn from €10bn at an immunology investor event on 29 March, a couple of days after presenting more promising data at the American Academy of Dermatology (AAD) meeting on the blockbuster in prurigo nodularis, which causes itchy bumps on the skin.

More from Dermatological

More from Therapy Areas